mind
Apathy
Adverse effectApathy is a mind-related adverse effect. It refers to a reported experience attributed to supplement use, including reports associated with 5-HTP, Ashwagandha, CBD (Cannabidiol), and Choline (Bitartrate).
Apathy is categorized as a mind-related effect, offering a focused starting point for exploring this topic.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What can cause it
How likely each one is to cause it, most likely first.
Tai ChipracticeUnclear
Based on one study. Strongest study: a systematic review of studies.
A 2025 systematic review described boredom with Tai Chi as slow and mundane; the study designs in the pooled analyses were not recorded.
Open the Tai Chi page
The expert view shows every study, dose protocol and source.
What can cause it
Interventions reported to bring this on1 listedHighest probability
- →PracticesTai ChiCertaintyLowSourceClinical1 other source
A 2025 systematic review described boredom with Tai Chi as slow and mundane; the study designs in the pooled analyses were not recorded.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Apathy is a mind-related adverse effect. It refers to a reported experience attributed to supplement use, including reports associated with 5-HTP, Ashwagandha, CBD (Cannabidiol), and Choline (Bitartrate). These associations are anecdotal and should not be understood as established clinical findings.
How interventions help
The interventions listed here are not established as ways to improve apathy. Instead, apathy appears as a possible unwanted experience associated with some uses, based on anecdotal reports rather than clinical findings. These reports do not show that any of the interventions reliably causes apathy, nor do they establish how often it occurs in people using them more broadly.
There is also no established dose, duration, onset, or persistence pattern for this outcome. The available reports cannot determine whether apathy is directly caused by an intervention, reflects another factor, or resolves after use changes. This makes the findings difficult to apply to a particular person or situation. Overall, the information is best understood as a signal to monitor for reduced motivation or emotional engagement, not as evidence that any listed intervention should be used to produce or relieve apathy.
Choosing guidance
Apathy is not well characterized as an outcome for any of the listed options. The associations are anecdotal rather than supported by clearly identified clinical study designs, so they do not establish that an option causes apathy or indicate how often this might occur in people using it under defined conditions.
There is no reliable basis here for choosing among 5-HTP, Ashwagandha, CBD (Cannabidiol), Choline (Bitartrate), Saw Palmetto, Taurine, Bacopa Monnieri, and Vitamin B9 (Folate) specifically to avoid apathy. The information does not establish a comparative dose, duration of use, or speed of onset, and it does not show whether reports are consistent across studies or populations.
Because the health status of the people represented is not specified, the observations may not apply to a particular person or clinical situation. These entries are better treated as signals to monitor rather than as evidence for predicting an individual response. If apathy appears or changes after starting an option, the timing and any accompanying changes may be useful to discuss with a qualified healthcare professional.